Marktprognose für kardiometabolische Erkrankungen in Süd- und Mittelamerika bis 2028 – Auswirkungen von COVID-19 und regionale Analyse nach Typ (Herz-Kreislauf-Erkrankung (CVD), Typ-2-Diabetes, Bluthochdruck und Fettleibigkeit), Behandlung (ACE-Hemmer, Diuretika, Glucophage und andere), Dosierung (Tablette und Injektion), Verabreichungsweg (oral und intravenös), Endbenutzer (Krankenhaus, Klinik und häusliche Pflege) und Vertriebskanal (Krankenhausapotheke, Einzelhandelsapotheke und Online-Apotheke)
Markteinführung
Die kardiometabolische Erkrankung ist durch eine Gruppe von Anomalien und Symptomen gekennzeichnet, die auftreten das Risiko, dass Personen eine Herz-Kreislauf-Erkrankung entwickeln. Zu den Symptomen gehören Bluthochdruck, Fettleibigkeit, Insulinresistenz, Dyslipidämie, schlechtes Cholesterinprofil (LDL) und Glukosetoleranz. Personen, die am kardiometabolischen Syndrom leiden, sind anfällig für mehrere andere lebensbedrohliche Krankheiten wie Typ-2-Diabetes, Schlaganfall, koronare Herzkrankheit (KHK), Herz-Kreislauf-Erkrankungen (CVD) und viele andere.
Darüber hinaus wird erwartet, dass die zunehmende Prävalenz kardiometabolischer Erkrankungen das Marktwachstum im Prognosezeitraum ankurbeln wird. Allerdings schränkt die Unterdiagnose von Herz-Kreislauf-Erkrankungen in Ländern mit niedrigem und mittlerem Einkommen (LMICs) das Wachstum des süd- und mittelamerikanischen Marktes für kardiometabolische Erkrankungen ein.
Brasilien, Argentinien, Uruguay, Chile , Peru, Kolumbien ist besorgt über die zweite Corona-Infektionswelle. Die Mehrzahl der Todesfälle verzeichnete dabei Brasilien. Es wird erwartet, dass die Region wahrscheinlich eine zweite Sperrung erzwingen wird, was letztendlich die Gesundheitsbranche in der Region beeinträchtigen wird. Während dieser COVID-19-Pandemie gab es intensive Versuche, eine medikamentöse Therapie zur Vorbeugung und Behandlung einer SARS-CoV-2-Infektion zu erforschen. Daher dürften die laufenden klinischen Studien zum Markt für kardiometabolische Erkrankungen für COVID in der Region das Wachstum des Marktes begünstigen.
Marktüberblick und -dynamik
Der süd- und mittelamerikanische Markt für kardiometabolische Erkrankungen wird in den USA bis 2028 voraussichtlich 10.295,5 Millionen US-Dollar erreichen 8.472,6 Millionen US-Dollar im Jahr 2021; Es wird erwartet, dass sie von 2021 bis 2028 mit einer jährlichen Wachstumsrate von 2,8 % wachsen wird. Der Wandel der Gesundheitsbranche von einer Einheitslösung hin zu einem zielgerichteten Ansatz steigert die Nachfrage nach personalisierten Medikamenten. Aufgrund der Fortschritte in der personalisierten Medizin, die auf der individuellen genetischen Struktur basiert, werden diese Medikamente immer mehr zum Markenzeichen der Behandlung chronischer Krankheiten. Die zunehmende Forschung zur Integration einer personalisierten Behandlung chronischer Krankheiten eröffnet neue therapeutische Wege. Auch Pharmariesen erforschen personalisierte Behandlungsmöglichkeiten für CMDs. Kürzlich erhielt Novartis von Akcea Therapeutics die Rechte zur Entwicklung und Vermarktung von TQJ230, einem Prüfpräparat für die gezielte Herz-Kreislauf-Therapie. Millionen von Menschen haben einen erhöhten Lipoproteinwert (a), einen unabhängigen vererbten Risikofaktor für Herz-Kreislauf-Erkrankungen, der durch Ernährung und andere Änderungen des Lebensstils nicht wirksam bekämpft werden kann. Im Falle einer Zulassung könnte TQJ230 die erste Behandlung dieser Klasse sein, die explizit auf erhöhte Lp(a) abzielt. Darüber hinaus unterstützen Fortschritte in der KI und Datenanalyse die Entwicklung des Krankheitsmanagements durch die Personalisierung von Medikamenten, um präzise Interventionen zu ermöglichen. Diese Faktoren haben den Wachstumskurs des süd- und mittelamerikanischen Marktes für kardiometabolische Erkrankungen beschleunigt.
Wichtige Marktsegmente
In Bezug auf die Art hatte das Segment der Herz-Kreislauf-Erkrankungen im Jahr 2020 den größten Anteil am Markt für kardiometabolische Erkrankungen in Süd- und Mittelamerika. In Bezug auf die Behandlung machte das Segment der ACE-Hemmer den größten Anteil aus In Bezug auf die Dosierung hatte das Tablettensegment im Jahr 2020 den größten Anteil am Markt für Herz-Kreislauf-Erkrankungen in Süd- und Mittelamerika. In Bezug auf die Art der Verabreichung entfiel das orale Segment für den größten Anteil am Markt für Herz-Kreislauf-Erkrankungen in Süd- und Mittelamerika im Jahr 2020. In Bezug auf den Endverbraucher hatte das Krankenhaussegment im Jahr 2020 den größten Anteil am Markt für Herz-Kreislauf-Erkrankungen in Süd- und Mittelamerika Das Segment für Krankenhausapotheken hatte im Jahr 2020 den größten Marktanteil.
Wichtige Quellen und Unternehmen gelistet
Einige wichtige primäre und sekundäre Quellen, auf die bei der Erstellung dieses Berichts über den Markt für kardiometabolische Erkrankungen in Süd- und Mittelamerika Bezug genommen wird, sind Unternehmenswebsites, Jahresberichte, Finanzberichte und nationale Regierungen Dokumente und statistische Datenbanken. Zu den wichtigsten im Bericht aufgeführten Unternehmen gehören Bayer AG, Novartis AG, Kowa Company, Ltd., Boehringer Ingelheim International Gmbh, Novo Nordisk A/S und AstraZeneca.
Bericht über Kaufgründe
- Um den Süden zu verstehen und Mittelamerikas Marktlandschaft für kardiometabolische Erkrankungen und identifizieren Sie Marktsegmente, die wahrscheinlich eine starke Rendite garantieren
- Um die sich ständig verändernde Marktlandschaft zu verstehen und im Wettbewerb vorne zu bleiben
- Effiziente Planung von Fusionen, Übernahmen und Partnerschaften im süd- und mittelamerikanischen Markt für Herz-Kreislauf-Erkrankungen durch Identifizierung von Segmenten mit den vielversprechendsten wahrscheinlichen Verkäufen
- < span>Um fundierte Geschäftsentscheidungen auf der Grundlage einer einfühlsamen und umfassenden Analyse der Marktleistung verschiedener Segmente zu treffen
- Um eine Marktumsatzprognose für den Markt für kardiometabolische Erkrankungen in Süd- und Mittelamerika zu erhalten basierend auf verschiedenen Segmenten für den Zeitraum 2021–2028
MARKTSEGMENTIERUNG FÜR KARDIOMETABOLISCHE ERKRANKUNGEN IN SÜD- UND MITTELAMERIKA
Nach Typ
- Herz-Kreislauf-Erkrankung (CVD)
- Typ-2-Diabetes
- Bluthochdruck
- Fettleibigkeit
Durch Behandlung
- ACE-Hemmer
- Diuretika
- Glucophage
- Andere
< span>Nach Dosierung
- Tablette
- Injektion
Über den Verabreichungsweg
- Mündlich
- Intravenös
Von Endbenutzern
- < span>Krankenhaus
- Klinik
- Homecare-Einstellungen
< span>Nach Vertriebskanal
- Krankenhausapotheke
- Einzelhandelsapotheke
- Online-Apotheke
Nach Land
- Süd- und Mittelamerika
- Brasilien
- Argentinien
- Übriges Süd- und Mittelamerika
Erwähnte Unternehmen
- Bayer AG
- Novartis AG ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 South and Central America Cardiometabolic Diseases market – By Country
2. South and Central America Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South and Central America Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. South and Central America Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. South and Central America Cardiometabolic Diseases Market – Regional Analysis
6.1 South and Central America Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. South and Central America Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. South and Central America Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. South and Central America Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. South and Central America Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. South and Central America Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. South and Central America Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. South and Central America Cardiometabolic Diseases Market – Geographic Analysis
13.1 South and Central America: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.3 South and Central America: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 South and Central America: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 South and Central America: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 South and Central America: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 South and Central America: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.8 South and Central America: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9 South and Central America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.1 Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.10 Brazil: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.11 Brazil: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.12 Brazil: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.13 Brazil: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.14 Brazil: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.15 Brazil: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.15.1 Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.15.1.1 Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.16 Argentina: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.17 Argentina: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.18 Argentina: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.19 Argentina: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.20 Argentina: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.21 Argentina: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.21.1 Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.21.1.1 Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.22 Rest of South and Central America: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.23 Rest of South and Central America: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.24 Rest of South and Central America: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.25 Rest of South and Central America: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.26 Rest of South and Central America: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.27 Rest of South and Central America: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on South and Central America Cardiometabolic Diseases Market
14.1 South and Central America: Impact Assessment of COVID-19 Pandemic
15. South and Central America Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Bayer AG
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Novartis AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Boehringer Ingelheim International GmbH
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novo Nordisk A/S
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 AstraZeneca
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 Kowa Company, Ltd.
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. South and Central America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. South and Central America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 3. South and Central America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. South and Central America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 5. South and Central America Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 6. South and Central America Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. Brazil Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Brazil Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 9. Brazil Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Brazil Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 11. Brazil Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 12. Brazil Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. Argentina Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. Argentina Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. Argentina Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. Argentina Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 17. Argentina Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 18. Argentina Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 19. Rest of South and Central America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. Rest of South and Central America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. Rest of South and Central America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. Rest of South and Central America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 23. Rest of South and Central America Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 24. Rest of South and Central America Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. Organic Developments in the Cardiometabolic Diseases Market
Table 26. Inorganic Developments in the Cardiometabolic Diseases Market
Table 27. Glossary of Terms, South and Central America Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. South and Central America Cardiometabolic Diseases Market Segmentation
Figure 2. South and Central America Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of South and Central America Cardiometabolic Diseases Market
Figure 4. South and Central America Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. South and Central America Cardiometabolic Diseases Market, Industry Landscape
Figure 6. South and Central America PEST Analysis
Figure 7. South and Central America Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. South and Central America Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. South and Central America: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. South and Central America Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 35. South and Central America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. Impact of COVID-19 Pandemic on South and Central America Cardiometabolic Diseases Market
Figure 40. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South and Central America cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South and Central America cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.